Exclusion Criteria include orthostatic hypotension, secondary hypertension, the estimated glomerular filtration rate (eGFR) of ≤30 mL/min/1.73 m2, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2 × upper limit of normal, elevated potassium > 5 mEq/L, received an investigational agent within the last 30 days, type 1 diabetes or poorly controlled type 2 diabetes mellitus, newly diagnosed type 2 diabetes mellitus, history of any cardiovascular event within 6 months prior to randomization, history of intolerance to subcutaneous injection. The gene discussed is GPT; the disease is secondary hypertension.